loading...| Preferred Name |
rifaximin |
|
| Synonyms |
Xifaxan |
|
| Definitions |
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61926" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61926" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000654589 |
|
| altLabel |
Xifaxan |
|
| CAS Registry |
80621-81-4 |
|
| cui |
C0073374 C1615611 |
|
| DATE FIRST PUBLISHED |
2009-09-08 |
|
| Date last modified |
2010-06-09 |
|
| definition |
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61926" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61926" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C61926 |
|
| notation |
CDR0000654589 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
rifaximin |
|
| tui |
T109 T121 |